Two new p-tau assays launched to advance Alzheimer’s research
Quanterix (MA, USA) launched two novel assays at the Alzheimer’s Association International Conference 2025 (AAIC; 27–31 July, Toronto, Canada).
At this year’s AAIC meeting, Quanterix commercially launched two novel blood-based phosphor-tau (p-tau) assays, p-Tau 205 and p-Tau 212, designed for earlier detection and broader applications in neurodegenerative disease research. Developed using Quanterix’s ultra-sensitive Simoa® digital immunoassay platform, these assays aim to advance tau-based Alzheimer’s profiling and position Quanterix as the first to market with both p-Tau 205 and p-Tau 212.
Due to their strong association with early onset and progressive stages of Alzheimer’s disease and neurodegeneration, tau phosphorylation sites are increasingly recognized as vital biomarkers for Alzheimer’s disease. These sites provide critical insights into the structural and functional changes of tau protein. Specifically, phosphorylation at threonine 205 highlights the loss of microtubule binding and alignment, while phosphorylation at threonine 212 reflects conformational changes enriched in disease states. The development of these blood-based biomarkers aims to enable early detection, facilitate monitoring of disease progression, offer potential therapeutic targets and help classify patients based on disease characteristics.
Masoud Toloue, CEO of Quanterix, commented:
“The addition of p‑Tau 205 and 212 strengthens our ability to support the scientific community in its pursuit of earlier detection, deeper understanding and more personalized treatment approaches for Alzheimer’s.”
You may also be interested in:
- P-tau217 Elevated in Newborns and Individuals with Alzheimer’s
- Validating a Fully Automated Blood Test for Alzheimer’s Disease
- Biomarker Test Could Detect Alzheimer’s Years Before Symptoms
These new assays follow Quanterix’s acquisition of Akoya Biosciences (MA, USA) earlier this year, establishing them as a leader in the neurology, oncology and immunology markets. More merger and acquisition updates from 2025.
“Combined with the recent integration of Akoya’s spatial biology platform, we are now uniquely positioned to offer researchers a multi-dimensional view of pathobiology—bridging the gap between soluble protein dynamics and spatial tissue context. By uniting two best-in-class technologies, we’re advancing the future of precision diagnostics across neurology, oncology, and immunology,” continued Toloue.
